1887

Abstract

Conventional methods for determining drug susceptibility of require several weeks to obtain results, limiting their usefulness; automated methods and those based on molecular biology techniques have been able to reduce the turnaround time, but their high cost and need for sophisticated equipment restrict their use in developing countries. The goal of the present study was to evaluate the diagnostic accuracy of a rapid (3–4 days) low-cost test based on the use of mycobacteriophage D29 to determine the susceptibility of strains of to rifampicin (RIF) and isoniazid (INH). Results obtained show that susceptibility testing for RIF has a high diagnostic accuracy as compared to the standard indirect proportion method on Löwenstein–Jensen medium (sensitivity 100 % and specificity 98 %). Given the association between the resistance to RIF and INH, which define multidrug resistance (MDR), this test seems suitable for rapid detection of MDR tuberculosis strains (=0.978). Susceptibility testing for INH using mycobacteriophage D29 had a good but lower diagnostic accuracy as compared to the standard method (sensitivity 80.4 % and specificity 80.8 %); the test would then be of limited usefulness in the management of tuberculosis patients. Further studies to determine the relationship of mycobacteriophage D29 tests to correlates of sensitivity to specific antituberculosis drugs are warranted.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.46622-0
2007-03-01
2020-01-24
Loading full text...

Full text loading...

/deliver/fulltext/jmm/56/3/360.html?itemId=/content/journal/jmm/10.1099/jmm.0.46622-0&mimeType=html&fmt=ahah

References

  1. Altman, D. ( 1991; ). Some common problems in medical research. In Practical Statistics for Medical Research, pp. 396–439. Edited by D. G. Altman. London: Chapman & Hall.
  2. Bardou, F., Quémard, A., Dupont, M., Horn, C., Marchal, G. & Daffé, M. ( 1996; ). Effects of isoniazid on ultrastructure of Mycobacterium aurum and Mycobacterium tuberculosis and on production of secreted proteins. Antimicrob Agents Chemother 40, 2459–2467.
    [Google Scholar]
  3. David, H., Clavel, S. & Clement, F. ( 1980a; ). Adsorption and growth of the bacteriophage D29 in selected mycobacteria. Ann Virol (Inst Pasteur) 131, 167–184.[CrossRef]
    [Google Scholar]
  4. David, H., Clavel, S., Clement, F. & Moniz-Pereira, J. ( 1980b; ). Effects of antituberculosis and antileprosy drugs on mycobacteriophage D29 growth. Antimicrob Agents Chemother 18, 357–359.[CrossRef]
    [Google Scholar]
  5. Eltringham, I., Drobniewski, F. A., Mangan, J. A., Butcher, P. D. & Wilson, S. M. ( 1999a; ). Evaluation of reverse transcription-PCR and a bacteriophage-based assay for rapid phenotypic detection of rifampin resistance in clinical isolates of Mycobacterium tuberculosis. J Clin Microbiol 37, 3524–3527.
    [Google Scholar]
  6. Eltringham, I., Wilson, S. & Drobniewski, F. ( 1999b; ). Evaluation of a bacteriophage-based assay (phage amplified biologically assay) as rapid screen for resistance to isoniazid, ethambutol, streptomycin, pyrazinamide, and ciprofloxacin among clinical isolates of Mycobacterium tuberculosis. J Clin Microbiol 37, 3528–3532.
    [Google Scholar]
  7. Galí, N., Domínguez, J., Blanco, S., Prat, C., Quesada, M., Matas, L. & Auxina, V. ( 2003; ). Utility of an in-house mycobacteriophage-based assay for rapid detection of rifampin resistance in Mycobacterium tuberculosis clinical isolates. J Clin Microbiol 41, 2647–2649.[CrossRef]
    [Google Scholar]
  8. Galí, N., Domínguez, J., Blanco, S., Prat, C., Alcaide, F., Coll, P. & Ausina, V. ( 2006; ). Use of a mycobacteriophage-based assay for rapid assessment of susceptibilities of Mycobacterium tuberculosis isolates to isoniazid and influence of resistance level on assay performance. J Clin Microbiol 44, 201–205.[CrossRef]
    [Google Scholar]
  9. Hanley, J. A. & McNeil, B. J. ( 1982; ). The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143, 29–36.[CrossRef]
    [Google Scholar]
  10. Hatfull, G. ( 1999; ). Mycobacteriophage. In Mycobacteria – Molecular Biology and Virulence, pp. 38–58. Edited by C. Ratledge & J. Dale. London: Blackwell.
  11. Hatfull, G. ( 2005; ). Mycobacteriophages: pathogenesis and applications. In Phages: Their Role in Bacterial Pathogenesis and Biotechnology, pp. 238–255. Edited by M. Waldor, D. Friedman & S. Adhya. Washington, DC: American Society for Microbiology.
  12. Heifets, L. (editor) ( 1991; ). Drug susceptibility test in the management of chemotherapy of tuberculosis. In Drug Susceptibility in the Chemotherapy of Mycobacterial Infections, pp. 90–115. Florida: CRC Press.
  13. Heifets, L. & Cangelosi, G. ( 1999; ). Drug susceptibility testing of Mycobacterium tuberculosis: a neglected problem at the turn of the century. Int J Tuberc Lung Dis 3, 564–581.
    [Google Scholar]
  14. Iseman, M. D. ( 1998; ). MDR-TB and the developing world – a problem no longer to be ignored: the WHO announces ‘DOTS Plus' strategy. Int J Tuberc Lung Dis 2, 867.
    [Google Scholar]
  15. Kent, P. T. & Kubica, G. P. ( 1985; ). Public Health Mycobacteriology: a Guide for the Level III Laboratory. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control.
  16. McNerney, R. ( 1999; ). TB: the return of the phage. A review of fifty years of mycobacteriophage research. Int J Tuberc Lung Dis 3, 179–184.
    [Google Scholar]
  17. McNerney, R., Wilson, S., Sidhu, A., Harley, V., Al-Suwanidi, Z., Nye, P., Parish, T. & Stoker, N. ( 1998; ). Inactivation of mycobacteriophage D29 using ferrous ammonium sulphate as a tool for the detection of viable Mycobacterium smegmatis and M. tuberculosis. Res Microbiol 149, 487–495.[CrossRef]
    [Google Scholar]
  18. McNerney, R., Kiepiela, P., Bishop, K., Nye, P. M. & Stoker, N. G. ( 2000; ). Rapid screening of Mycobacterium tuberculosis for susceptibility to rifampicin and streptomycin. Int J Tuberc Lung Dis 4, 69–75.
    [Google Scholar]
  19. Shapiro, D. ( 1999; ). The interpretation of diagnostic tests. Stat Methods Med Res 8, 113–134.[CrossRef]
    [Google Scholar]
  20. Símboli, N., Takiff, H., McNerney, R., Lopez, B., Martin, A., Palomino, J. C., Barrera, L. & Ritacco, V. ( 2005; ). In-house phage amplification assay is a sound alternative for detecting rifampin-resistant Mycobacterium tuberculosis in low-resource settings. Antimicrob Agents Chemother 49, 425–427.[CrossRef]
    [Google Scholar]
  21. Swets, J. ( 1988; ). Measuring the accuracy of diagnostic systems. Science 240, 1285–1293.[CrossRef]
    [Google Scholar]
  22. Tortoli, E., Benedetti, M., Fontanelli, A. & Simonetti, M. ( 2002; ). Evaluation of automated BACTEC MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to four major antituberculous drugs: comparison with the radiometric BACTEC 460TB method and the agar plate method of proportion. J Clin Microbiol 40, 607–610.[CrossRef]
    [Google Scholar]
  23. Watterson, S. & Drobniewski, F. ( 2000; ). Modern laboratory diagnosis of mycobacterial infections. J Clin Pathol 53, 727–732.[CrossRef]
    [Google Scholar]
  24. Watterson, S., Wilson, S., Yates, W. & Drobniewski, F. ( 1998; ). Comparison of three molecular assays for rapid detection of rifampin resistance in Mycobacterium tuberculosis. J Clin Microbiol 36, 1969–1973.
    [Google Scholar]
  25. Wilson, S., Al-Suwaidi, Z., McNerney, R., Porter, J. & Drobniewski, F. ( 1997; ). Evaluation of a new rapid bacteriophage-based method for the drug susceptibility testing of Mycobacterium tuberculosis. Nat Med 34, 465–468.
    [Google Scholar]
  26. World Health Organization ( 1997; ). Global Tuberculosis Programme. Anti-Tuberculosis Drug Resistance in the World. The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance 1994–1997. Annex 2 – Individual Country Profiles. WHO/TB/97.229. Geneva: World Health Organization.
  27. World Health Organization ( 1998; ). Guidelines for surveillance of drug resistance in tuberculosis. Int J Tuberc Lung Dis 2, 72–89.
    [Google Scholar]
  28. World Health Organization ( 2005; ). WHO Report 2005. Global Tuberculosis Control – Surveillance, Planning, Financing. WHO/HTM/TB/2005.349. Geneva: World Health Organization.
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.46622-0
Loading
/content/journal/jmm/10.1099/jmm.0.46622-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error